Safety and efficacy of eblasakimab, an IL-13R alpha 1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. Supplementary information.

Name: Safety and efficacy of eblasakimab, an IL-13R alpha 1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. Supplementary information.
Creator: Karen Veverka
Published: 2023-10-16T06:06:49.349Z
Keywords: Dermatology

Veverka, Karen; Thng, Steven; Silverberg, Jonathan; Armstrong, April; Kaoukhov, Alexandre; Blauvelt, Andrew

doi:10.17632/g6m6884znc.1

Safety and efficacy of eblasakimab, an IL-13R alpha 1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. Supplementary information.

Published: 16 October 2023| Version 1 | DOI: 10.17632/g6m6884znc.1

Contributors:

Karen Veverka, Steven Thng, Jonathan Silverberg, April Armstrong, Alexandre Kaoukhov, Andrew Blauvelt

Description

This dataset contains figures, tables, and documents referenced in: Safety and efficacy of eblasakimab, an IL-13R alpha 1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. (Blauvelt et al.)

Safety and efficacy of eblasakimab, an IL-13R alpha 1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. Supplementary information.

Description

Files

Categories

Licence